What is he best known for?
The fields of study he is best known for:
- Gene
- Enzyme
- Signal transduction
Michael J. Weber focuses on Mitogen-activated protein kinase kinase, Biochemistry, Signal transduction, MAPK/ERK pathway and Kinase.
His Mitogen-activated protein kinase kinase research is multidisciplinary, incorporating perspectives in MAP2K7, Molecular biology and MAP kinase kinase kinase.
His research in MAP kinase kinase kinase intersects with topics in Scaffold protein and Cellular differentiation.
Signal transduction is a subfield of Cell biology that Michael J. Weber explores.
His studies examine the connections between Cell biology and genetics, as well as such issues in Cancer research, with regards to Akt/PKB signaling pathway, Protein kinase B and Tyrosine phosphorylation.
His MAPK/ERK pathway study combines topics in areas such as Mitogen-activated protein kinase, Endocrinology, Growth factor and Internal medicine.
His most cited work include:
- Mitogen-activated protein kinases: specific messages from ubiquitous messengers (1417 citations)
- ANTIAPOPTOTIC SIGNALLING BY THE INSULIN-LIKE GROWTH FACTOR I RECEPTOR, PHOSPHATIDYLINOSITOL 3-KINASE, AND AKT (982 citations)
- Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase). (891 citations)
What are the main themes of his work throughout his whole career to date?
Michael J. Weber mainly focuses on Cancer research, Cell biology, Biochemistry, Signal transduction and Kinase.
His studies in Cancer research integrate themes in fields like Cancer cell, Cell signaling, PI3K/AKT/mTOR pathway and Protein kinase B.
The study incorporates disciplines such as Integrin and Cell migration in addition to Cell biology.
The Signal transduction study combines topics in areas such as Receptor, Growth inhibition, Pharmacology and Prostate cancer.
Michael J. Weber has included themes like Function and Phosphorylation in his Kinase study.
His Mitogen-activated protein kinase kinase study deals with MAP2K7 intersecting with MAP kinase kinase kinase, MAPK14 and Casein kinase 2, alpha 1.
He most often published in these fields:
- Cancer research (31.75%)
- Cell biology (25.40%)
- Biochemistry (25.40%)
What were the highlights of his more recent work (between 2011-2021)?
- Cancer research (31.75%)
- Ibrutinib (10.32%)
- Signal transduction (26.98%)
In recent papers he was focusing on the following fields of study:
Cancer research, Ibrutinib, Signal transduction, Chronic lymphocytic leukemia and Venetoclax are his primary areas of study.
His study in Cancer research is interdisciplinary in nature, drawing from both Cancer cell, Apoptosis and Cell signaling.
His Signal transduction study frequently links to other fields, such as Integrin.
Michael J. Weber has researched Chronic lymphocytic leukemia in several fields, including Agonist and Bruton's tyrosine kinase.
His PI3K/AKT/mTOR pathway research includes themes of Mitogen-activated protein kinase, Phosphorylation and MAPK/ERK pathway.
His Cancer research is multidisciplinary, incorporating elements of Mesenchymal stem cell, Diacylglycerol Kinase Alpha, Diacylglycerol kinase and Biochemistry.
Between 2011 and 2021, his most popular works were:
- The state of melanoma: challenges and opportunities (48 citations)
- Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms (37 citations)
- Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. (32 citations)
In his most recent research, the most cited papers focused on:
Michael J. Weber mainly investigates Pharmacology, Signal transduction, Mantle cell lymphoma, Ibrutinib and Chronic lymphocytic leukemia.
His Pharmacology research incorporates elements of Cell, MEK inhibitor, MAPK/ERK pathway and Small molecule.
His Signal transduction study incorporates themes from Cyclooxygenase, Cancer research and Genetic screen.
His Cancer research research is multidisciplinary, relying on both Cancer cell, Diacylglycerol Kinase Alpha, Biochemistry, Mesenchymal stem cell and RHOA.
His Ibrutinib study integrates concerns from other disciplines, such as Proteasome inhibitor, Survivin, Agonist, Venetoclax and Drug resistance.
In his study, Drug is strongly linked to Proteasome, which falls under the umbrella field of Bruton's tyrosine kinase.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
